Advertisement

Increased Utilization of Stereotactic Body Radiotherapy is Associated with Decreased Disparities and Improved Survival for Early-Stage NSCLC

Published:September 23, 2022DOI:https://doi.org/10.1016/j.cllc.2022.09.006

      Abstract

      Introduction

      We sought to determine if increased use of stereotactic body radiation therapy (SBRT) was associated with decreased disparities in the receipt of definitive treatment for early-stage non-small cell lung cancer (NSCLC).

      Methods

      The National Cancer Database (NCDB) was utilized to determine the proportion of patients with NSCLC receiving surgery, SBRT, or no definitive treatment for clinical cT1-2aN0M0 NSCLC from 2004-2017. Univariable and multivariable logistic regressions were used. Age-adjusted mortality rates were calculated using the Surveillance, Epidemiology, and End Result (SEER) database.

      Results

      From 2004 to 2017, the proportion of early-stage NSCLC undergoing no definitive treatment declined from 22% to 10.5% (P<.001), while the proportion receiving SBRT increased from 1% (0.9%-1.3%) to 22% (21.4%-22.3%; P<.001). Among Whites, the proportion undergoing no definitive treatment decreased from 21% to 10% (P<.001), as compared to Blacks, which had a higher decrease, of 32% to 15% (P<.001). The proportion of Blacks receiving SBRT increased from 1% (0.3%-1.7%) to 22% (20.8%-23.5%) (P<.001). Between 2011 and 2017 likelihood of Blacksreceiving curative therapy increased compared to Whites [OR: 0.55 (0.48-0.64) to 0.70 (0.62-0.79; P<.001]. Furthermore, the age-adjusted mortality rate of early-stage NSCLC decreased from 4.3 (4.0-4.5) in 2004 to 0.8 (0.7-0.9) in 2017 (P<.001).

      Conclusions

      Increased utilization of SBRT significantly increased the proportion of patients receiving curative therapy for early-stage NSCLC and was associated with an improvement in mortality.  Furthermore, the use of SBRT reduced previously seen disparities in receipt of treatment between Whites and Blacks. SBRT was also associated with decreased mortality from early-stage NSCLC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bach PB
        • Cramer LD
        • Warren JL
        • Begg CB.
        Racial Differences in the Treatment of Early-Stage Lung Cancer.
        N Engl J Med. 1999; 341: 1198-1205https://doi.org/10.1056/NEJM199910143411606
        • Harrison S
        • Judd J
        • Chin S
        • Ragin C.
        Disparities in Lung Cancer Treatment.
        Curr Oncol Rep. 2022; 24: 241-248https://doi.org/10.1007/s11912-022-01193-4
        • Blom EF
        • ten Haaf K
        • Arenberg DA
        • de Koning HJ.
        Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States.
        Ann Am Thorac Soc. 2020; 17: 186-194https://doi.org/10.1513/AnnalsATS.201901-094OC
        • Merkow RP
        • Rademaker AW
        • Bilimoria KY.
        Practical Guide to Surgical Data Sets: National Cancer Database (NCDB).
        JAMA Surg. 2018; 153: 850https://doi.org/10.1001/jamasurg.2018.0492
        • Howlader N
        • Forjaz G
        • Mooradian MJ
        • et al.
        The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
        N Engl J Med. 2020; 383: 640-649https://doi.org/10.1056/NEJMoa1916623
        • Ramaswamy A.
        Lung Cancer Screening: Review and 2021 Update.
        Curr Pulmonol Rep. 2022; 11: 15-28https://doi.org/10.1007/s13665-021-00283-1
        • Arbour KC
        • Riely GJ.
        Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review.
        JAMA. 2019; 322: 764https://doi.org/10.1001/jama.2019.11058
        • Jones GS
        • Baldwin DR.
        Recent advances in the management of lung cancer.
        Clin Med Lond Engl. 2018; 18: s41-s46https://doi.org/10.7861/clinmedicine.18-2-s41
        • Raz DJ
        • Zell JA
        • Ou SHI
        • Gandara DR
        • Anton-Culver H
        • Jablons DM
        Natural History of Stage I Non-Small Cell Lung Cancer.
        Chest. 2007; 132: 193-199https://doi.org/10.1378/chest.06-3096
        • Arpey NC
        • Gaglioti AH
        • Rosenbaum ME.
        How Socioeconomic Status Affects Patient Perceptions of Health Care: A Qualitative Study.
        J Prim Care Community Health. 2017; 8: 169-175https://doi.org/10.1177/2150131917697439
      1. Griffith K, Evans L, Bor J. The Affordable Care Act Reduced Socioeconomic Disparities In Health Care Access. Health Aff (Millwood). 2017;36(8):1503-1510. 10.1377/hlthaff.2017.0083

        • McMaughan DJ
        • Oloruntoba O
        • Smith ML.
        Socioeconomic Status and Access to Healthcare: Interrelated Drivers for Healthy Aging.
        Front Public Health. 2020; 8: 231https://doi.org/10.3389/fpubh.2020.00231
        • McDuffie DL
        • Kouchi K
        • Dorman H
        • Bownes E
        • Condon SE
        • Grief Crowther MR.
        COVID-19, and the South: Considerations and Recommendations.
        OMEGA - J Death Dying. July 1, 2021; (Published online003022282110295)https://doi.org/10.1177/00302228211029500
        • Jairam V
        • Park HS.
        Strengths and limitations of large databases in lung cancer radiation oncology research.
        Transl Lung Cancer Res. 2019; 8: S172-S183https://doi.org/10.21037/tlcr.2019.05.06
        • Murthy VH
        • Krumholz HM
        • Gross CP.
        Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities.
        JAMA. 2004; 291: 2720https://doi.org/10.1001/jama.291.22.2720
        • Unger JM
        • Hershman DL
        • Fleury ME
        • Vaidya R.
        Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation.
        JAMA Oncol. 2019; 5: 326https://doi.org/10.1001/jamaoncol.2018.5953